Nicolas Serandour, CEO of Advanced Oncotherapy (AVO), discusses the details of the technological update and the significant progress in validating the capabilities of the first in the next group of accelerating components with BRR Media. Following these successful trials, the Company remains on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018.